The state enterprise "ACADEMPHARM" of the NASB won in the nomination "INNOVATION OF THE YEAR" of the competition for the Eurasian Pharma Award, which was held within the framework of the Eurasian Pharmaceutical Summit - 2021 (Tashkent, Uzbekistan). The award was received for the timeliness and innovativeness of the institution's developments, for the introduction of the first generic drug of rivaroxaban, Rivaksan, on the Belarusian market. This drug is intended for the prevention and treatment of complications of cardiovascular diseases associated with an increased risk of blood clots.

The Eurasian Pharmaceutical Summit - 2021 (Tashkent, Uzbekistan) was held on October 12-13, 2021. The forum discussed trends in the development of pharmaceutical markets, special aspects of drug registration in 13 countries: Russia, Kazakhstan, Uzbekistan, Kyrgyzstan, Belarus, Armenia, Azerbaijan, Tajikistan, Turkmenistan, Ukraine, Georgia, Moldova and Mongolia. Within the framework of the Eurasian Pharmaceutical Summit, a competition was held for the Eurasian Pharma Awards in 16 nominations.

The victory in this prestigious competition will allow the State Enterprise "ACADEMPHARM" of the NASB to increase the competitiveness of the enterprise in the markets of the EurAsEC countries.